Navigation Links
Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
Date:4/19/2012

pean Association of the Study of the Liver (EASL 2012) in Barcelona, Spain (Abstract #101). These results supplement the abstract findings highlighted today during an official EASL press conference.

"We are looking forward to the final results from this study, that we hope will be a significant step towards an interferon-free future for patients with HCV," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We are committed to the millions of people around the world who are chronically infected with HCV. Through our clinical trial program HCVerso™, we are working with experts worldwide to ask the difficult questions that remain in HCV to find answers to the challenges that these patients face."

Planning of the interferon-free Phase 3 clinical trial program is underway.

SOUND-C2 Pre-Specified Interim AnalysisIn this open-label Phase 2b study, 362 treatment-naive GT1 HCV patients were randomized into five interferon-free treatment groups, each with 120 mg BI 201335 QD, but with different dosing of BI 207127 and treatment durations. The randomization was stratified by HCV genotype (1a or 1b) and patient IL-28B genotype, with 41 percent of patients being GT1a and 75 percent being IL-28B CT or TT.SOUND-C2 Trial Design and Interim ResultsBI 201335

BI 207127

RBV

Treatment
Duration

SVR12
n (%)A

N=81

120 mg QD

600 mg TID

Y

16 wks

48 (59%)N=80

120 mg QD

600 mg TID

Y

28 wks

49 (61%)C

N=77

120 mg QD

600 mg TID

Y

40 wks

N/A*D

N=78

120 mg QD

600 mg BID

Y

28 wks

53 (68%)E

N=46

120 mg QD

600 mg TID

N

28 wks

18 (39%)* SVR12 data for the 40 week arm of SOUND-C2 is n
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
2. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
3. Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
4. QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
5. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
6. UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
7. Bionovos Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™
8. Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
9. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
10. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
11. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... NORRITON, Pa., Aug. 15, 2011 Tengion, Inc. (Nasdaq: ... Jorkasky, M.D., who recently joined Endo Pharmaceuticals (Nasdaq: ... Medical Officer, to its Board of Directors. ... at Quaker BioVentures, is stepping down from the Tengion Board ...
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... its second quarter 2011 financial results for the period ended June ... second quarter. Updates since the beginning of the ... Multiple Sclerosis (MS) As ...
Cached Medicine Technology:Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors 2Adeona Reports Second Quarter 2011 Financial Results 2Adeona Reports Second Quarter 2011 Financial Results 3Adeona Reports Second Quarter 2011 Financial Results 4Adeona Reports Second Quarter 2011 Financial Results 5Adeona Reports Second Quarter 2011 Financial Results 6Adeona Reports Second Quarter 2011 Financial Results 7Adeona Reports Second Quarter 2011 Financial Results 8Adeona Reports Second Quarter 2011 Financial Results 9
(Date:7/13/2014)... optical imaging device developed at Cedars-Sinai can provide ... the brain and are a classic sign of ... conducting a clinical trial in Australia. , The ... an oral presentation at the Alzheimer,s Association International ... invited by conference organizers to participate in a ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A ... & Schulte LLC to provide consumers with the most ... accompany use of the blood-thinning medication, as well as ... pending in courts around the country. The law firm ... may have suffered from life-threatening internal bleeding and related ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
(Date:7/12/2014)... to the new market research report "Security and Surveillance ... - Global Forecasts and Analysis to 2014 - 2020", ... estimated to be $6.08 billion in 2014 and are ... $8.61 billion by 2020. , Browse more than 93 ... pages and in-depth TOC on "Security and Surveillance Radar ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The Passenger ... million in 2013 to $20,341.36 million by 2019, at ... 2013 and 2019. , The public transport infrastructure in ... is also available in almost every corner of the ... the interest of public transport service providers are driving ...
Breaking Medicine News(10 mins):Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4
... "an illegal alien mother is not a deemed newborn" ... undocumented mothers of new// borns must apply for Medicaid. ... automatic for all babies whose mothers received emergency Medicaid coverage ... could leave babies without access to essential medical care such ...
... the eye cancer retinoblastoma has been developed by scientists ... a mouse model to cause a remarkable reduction in ... effects common with standard chemotherapy. In addition the treatment ... breast, lung, prostate and colon cancer, and is simple ...
... chronic obstructive pulmonary disease (COPD) attempt to repair damaged elastic ... is in contradiction with the conventional wisdom on the capabilities ... could pave the way to develop a drug to 'turn ... alveoli. ,The study "Evidence for attempted regional elastic ...
... human beings has found that concerns over the rise in ... still held in esteem and very much in demand. The ... ,The research has gathered details from 59 countries, which ... of live-in relationships and marriage figured on their wish-list. ...
... by more action and less talk according to opposition parties, ... on drinks. ,Leading doctors have launched a new ... raise awareness of alcohol-related health problems and push for action ... Conservative parties say the Executive needs to deal with the ...
... been found to have more sugar and fat than ... ,While each of these f 20 well-known bars, mostly ... sugar" under the Food Standards Agency's traffic light labeling ... more sugar (10g) than a chocolate Penguin bar (9.7g).,according ...
Cached Medicine News:Health News:Revolutionary Eye Cancer Treatment 2Health News:Revolutionary Eye Cancer Treatment 3Health News:Revolutionary Eye Cancer Treatment 4Health News:Lungs repair themselves 2Health News:Alcohol Abuse Must be solved with Action 2Health News:Cereal Bars Slammed for More Sugar Than Sweet Snacks 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: